Your browser doesn't support javascript.
loading
Meta-analysis of randomized trials on access site selection for percutaneous coronary intervention in ST-segment elevation myocardial infarction.
Komócsi, András; Aradi, Dániel; Kehl, Dániel; Ungi, Imre; Thury, Attila; Pintér, Tünde; Di Nicolantonio, James J; Tornyos, Adrienn; Vorobcsuk, András.
Afiliação
  • Komócsi A; Heart Institute, University of Pécs, Hungary.
  • Aradi D; Heart Institute, University of Pécs, Hungary.
  • Kehl D; Department of Statistics and Econometrics, Faculty of Business and Economics, University of Pécs, Hungary.
  • Ungi I; Invasive Cardiology Unit, Cardiology Center, University of Szeged, Hungary.
  • Thury A; Invasive Cardiology Unit, Cardiology Center, University of Szeged, Hungary.
  • Pintér T; Heart Institute, University of Pécs, Hungary.
  • Di Nicolantonio JJ; Wegmans Pharmacy, Ithaca, New York, USA.
  • Tornyos A; Heart Institute, University of Pécs, Hungary.
  • Vorobcsuk A; Heart Institute, University of Pécs, Hungary.
Arch Med Sci ; 10(2): 203-12, 2014 May 12.
Article em En | MEDLINE | ID: mdl-24904651
ABSTRACT

INTRODUCTION:

Superior outcomes with transradial (TRPCI) versus transfemoral coronary intervention (TFPCI) in the setting of acute ST-segment elevation myocardial infarction (STEMI) have been suggested by earlier studies. However, this effect was not evident in randomized controlled trials (RCTs), suggesting a possible allocation bias in observational studies. Since important studies with heterogeneous results regarding mortality have been published recently, we aimed to perform an updated review and meta-analysis on the safety and efficacy of TRPCI compared to TFPCI in the setting of STEMI. MATERIAL AND

METHODS:

Electronic databases were searched for relevant studies from January 1993 to November 2012. Outcome parameters of RCTs were pooled with the DerSimonian-Laird random-effects model.

RESULTS:

Twelve RCTs involving 5,124 patients were identified. According to the pooled analysis, TRPCI was associated with a significant reduction in major bleeding (odds ratio (OR) 0.52 (95% confidence interval (CI) 0.38-0.71, p < 0.0001)). The risk of mortality and major adverse events was significantly lower after TRPCI (OR = 0.58 (95% CI 0.43-0.79), p = 0.0005 and OR = 0.67 (95% CI 0.52-0.86), p = 0.002 respectively).

CONCLUSIONS:

Robust data from randomized clinical studies indicate that TRPCI reduces both ischemic and bleeding complications in STEMI. These findings support the preferential use of radial access for primary PCI.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Systematic_reviews Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Systematic_reviews Idioma: En Ano de publicação: 2014 Tipo de documento: Article